Bio-Rad Swings to Q3 Loss on Equity Valuation Hit

TL;DR

**BIO-RAD's Q3 net loss is a red flag, driven by massive investment valuation swings, not core business weakness, but still a hit to shareholder value.**

AI Summary

BIO-RAD LABORATORIES, INC. reported a net loss of $341.9 million for the three months ended September 30, 2025, a significant decline from a net income of $653.2 million in the same period of 2024. This was primarily driven by a $495.3 million loss from the change in fair market value of equity securities and loan receivable in Q3 2025, contrasting sharply with a $792.9 million gain in Q3 2024. Net sales saw a slight increase to $653.0 million in Q3 2025 from $649.7 million in Q3 2024. Gross profit decreased to $343.4 million from $355.9 million year-over-year, while research and development expenses decreased to $71.3 million from $91.0 million. For the nine months ended September 30, 2025, the company reported a net income of $39.9 million, a substantial improvement from a net loss of $1,128.4 million in the prior year, largely due to a smaller loss from equity securities valuation ($129.1 million in 2025 vs. $1,680.3 million in 2024). Total assets increased to $9,696.4 million as of September 30, 2025, from $9,364.1 million at December 31, 2024, with goodwill increasing by $168.2 million to $578.7 million, indicating recent acquisitions. Cash and cash equivalents decreased to $395.8 million from $488.1 million over the same period.

Why It Matters

This filing reveals a significant shift in BIO-RAD's financial performance, primarily due to the volatile fair market value of its equity securities and loan receivable. For investors, this highlights the substantial impact of non-operating factors on the bottom line, overshadowing a slight increase in net sales. The competitive landscape in the life science and clinical diagnostics markets means that consistent operational profitability is crucial, and these large swings in investment gains/losses can obscure underlying business health. Employees and customers might see this as a sign of financial instability, though the core business revenue remains relatively stable. The broader market will watch how BIO-RAD manages its investment portfolio and whether operational improvements can offset such volatility, especially given the increase in goodwill suggesting recent M&A activity.

Risk Assessment

Risk Level: high — The company experienced a $495.3 million loss from the change in fair market value of equity securities and loan receivable for the three months ended September 30, 2025, compared to a $792.9 million gain in the prior year. This extreme volatility in non-operating income, which directly led to a net loss of $341.9 million, indicates a high level of financial risk tied to market fluctuations of its investments, rather than its core business operations.

Analyst Insight

Investors should scrutinize BIO-RAD's investment portfolio, particularly its equity securities and loan receivable, as these are driving significant earnings volatility. While the core business appears relatively stable, the substantial non-operating losses warrant a deeper dive into the nature and risk profile of these investments before making any long-term decisions.

Financial Highlights

debt To Equity

0.44

revenue

$653.0M

operating Margin

N/A

total Assets

$9,696.4M

total Debt

$1,202.7M

net Income

-$341.9M

eps

-$12.68

gross Margin

52.6%

cash Position

$395.8M

revenue Growth

+0.5%

Key Numbers

• $341.9M — Net Loss (Q3 2025) (Significant swing from $653.2M net income in Q3 2024)
• $495.3M — Loss from Equity Securities Valuation (Q3 2025) (Primary driver of net loss, contrasting with $792.9M gain in Q3 2024)
• $653.0M — Net Sales (Q3 2025) (Slight increase from $649.7M in Q3 2024)
• $71.3M — R&D Expense (Q3 2025) (Decrease from $91.0M in Q3 2024)
• $39.9M — Net Income (9M 2025) (Improvement from $1,128.4M net loss in 9M 2024)
• $129.1M — Loss from Equity Securities Valuation (9M 2025) (Significantly less than $1,680.3M loss in 9M 2024)
• $9,696.4M — Total Assets (Sep 30, 2025) (Increased from $9,364.1M at Dec 31, 2024)
• $578.7M — Goodwill, net (Sep 30, 2025) (Increased by $168.2M from $410.5M at Dec 31, 2024, indicating acquisitions)
• $395.8M — Cash and Cash Equivalents (Sep 30, 2025) (Decreased from $488.1M at Dec 31, 2024)
• 26,923 — Weighted Average Common Shares - Basic (Q3 2025) (Decreased from 27,949 in Q3 2024)

Key Players & Entities

• BIO-RAD LABORATORIES, INC. (company) — registrant
• Sartorius AG (company) — risk factor related to position in company
• $341.9 million (dollar_amount) — net loss for three months ended September 30, 2025
• $653.2 million (dollar_amount) — net income for three months ended September 30, 2024
• $495.3 million (dollar_amount) — loss from change in fair market value of equity securities and loan receivable for Q3 2025
• $792.9 million (dollar_amount) — gain from change in fair market value of equity securities and loan receivable for Q3 2024
• $653.0 million (dollar_amount) — net sales for three months ended September 30, 2025
• $71.3 million (dollar_amount) — research and development expense for three months ended September 30, 2025
• $91.0 million (dollar_amount) — research and development expense for three months ended September 30, 2024
• $578.7 million (dollar_amount) — Goodwill, net as of September 30, 2025

FAQ

Risk Factors

• Fair Value Fluctuations of Investments [high — market]: The company experienced a significant loss of $495.3 million in Q3 2025 due to changes in the fair market value of equity securities and loan receivable. This contrasts sharply with a $792.9 million gain in the prior year's quarter, highlighting the volatility and impact of investment valuations on net income.
• Integration of Acquisitions [medium — operational]: An increase in goodwill by $168.2 million to $578.7 million indicates recent acquisitions. The successful integration of these acquired businesses is crucial for realizing their intended value and avoiding potential impairment charges.
• Decreasing Cash Reserves [medium — financial]: Cash and cash equivalents decreased by $92.3 million to $395.8 million as of September 30, 2025, from $488.1 million at December 31, 2024. This reduction in liquidity may impact the company's ability to fund operations, investments, or debt obligations.
• Rising Debt Levels [medium — financial]: Total liabilities increased to $2,959.6 million from $2,794.8 million. While long-term debt remained relatively stable at $1,201.4 million, the overall increase in liabilities, coupled with decreased cash, warrants attention.
• Gross Profit Margin Compression [medium — market]: Gross profit decreased to $343.4 million in Q3 2025 from $355.9 million in Q3 2024, despite a slight increase in net sales. This indicates pressure on pricing or an increase in the cost of goods sold, impacting overall profitability.

Industry Context

Bio-Rad Laboratories operates in the life science research and clinical diagnostics markets. The industry is characterized by continuous innovation, demand for advanced analytical tools, and stringent regulatory oversight. Key trends include the growth of personalized medicine, advancements in genomics and proteomics, and the increasing use of automation in laboratories.

Regulatory Implications

As a provider of diagnostic and research tools, Bio-Rad is subject to regulations from bodies like the FDA and international equivalents. Compliance with quality standards, data privacy (e.g., HIPAA), and product approval processes are critical. Changes in healthcare policy or reimbursement rates can also impact demand for its products.

What Investors Should Do

1. Monitor Investment Valuation Impact
2. Analyze Acquisition Integration
3. Evaluate Operational Profitability
4. Assess Cash Flow and Liquidity

Key Dates

• 2025-09-30: End of Q3 2025 — Reported a net loss of $341.9 million, heavily influenced by investment valuation losses. Total assets reached $9,696.4 million.
• 2024-09-30: End of Q3 2024 — Reported a net income of $653.2 million, boosted by significant gains from equity securities valuation.
• 2025-12-31: End of Fiscal Year 2024 — Total assets were $9,364.1 million, with cash and cash equivalents at $488.1 million.

Glossary

Goodwill, net

An intangible asset representing the excess of the purchase price of an acquired company over the fair value of its identifiable net assets. It reflects the value of brand reputation, customer relationships, etc. (An increase of $168.2 million to $578.7 million suggests recent acquisitions, which are key to the company's growth strategy but also carry integration risks.)

Accumulated other comprehensive loss

A component of equity that includes unrealized gains and losses on certain investments, foreign currency translation adjustments, and pension adjustments that have not yet been realized. (A reduction from a loss of $538.2 million to $166.8 million indicates favorable changes in these unrealized items, partially offsetting the net loss.)

Change in fair market value of equity securities and loan receivable

The gain or loss resulting from fluctuations in the market price of stocks and other equity investments, as well as changes in the value of loans held by the company. (This line item was the primary driver of the significant net loss in Q3 2025 ($495.3 million loss) and the net income in Q3 2024 ($792.9 million gain), demonstrating extreme volatility.)

Weighted Average Common Shares - Basic

The average number of outstanding common shares during a period, used to calculate earnings per share (EPS). (A decrease from 27,949 thousand in Q3 2024 to 26,923 thousand in Q3 2025 means that the net income or loss is spread over fewer shares, potentially amplifying EPS fluctuations.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Bio-Rad Laboratories reported a dramatic shift from a $653.2 million net income to a $341.9 million net loss. This swing was primarily driven by a $495.3 million loss from equity securities valuation in the current period, versus a $792.9 million gain in the prior year. While net sales saw a marginal increase to $653.0 million, gross profit decreased, and R&D expenses were reduced. Total assets grew, largely due to an increase in goodwill reflecting acquisitions, but cash reserves declined.

Key Financial Figures

• $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange

Filing Documents

• bio-20250930.htm (10-Q) — 1511KB
• ex31193025.htm (EX-31.1) — 11KB
• ex31293025.htm (EX-31.2) — 11KB
• ex32193025.htm (EX-32.1) — 6KB
• ex32293025.htm (EX-32.2) — 6KB
• 0000012208-25-000077.txt ( ) — 9523KB
• bio-20250930.xsd (EX-101.SCH) — 39KB
• bio-20250930_cal.xml (EX-101.CAL) — 77KB
• bio-20250930_def.xml (EX-101.DEF) — 346KB
• bio-20250930_lab.xml (EX-101.LAB) — 662KB
• bio-20250930_pre.xml (EX-101.PRE) — 512KB
• bio-20250930_htm.xml (XML) — 1805KB

– Financial Information

Part I – Financial Information 4

Financial Statements

Item 1. Financial Statements 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Income (Loss) 6 Condensed Consolidated Statements of Comprehensive Income (Loss) 7 Condensed Consolidated Statements of Cash Flows 8 Condensed Consolidated Statements of Changes in Stockholders' Equity 9 Notes to Condensed Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 33

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 38

Controls and Procedures

Item 4. Controls and Procedures 38

– Other Information

Part II – Other Information 39

Legal Proceedings

Item 1. Legal Proceedings 39

Risk Factors

Item 1A. Risk Factors 40

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 53

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 53

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 53

Other Information

Item 5. Other Information 53

Exhibits

Item 6. Exhibits 54

Signatures

Signatures 55 2 INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS Other than statements of historical fact, statements made in this report include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our future financial performance, operating results, plans and objectives. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," "seek," "future," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, the risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, supply chain issues, risks associated with our position in Sartorius AG, risks to our information technology systems, intellectual property risks, our ability to attract and retain key personnel, international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, natural disasters and other catastrophic events beyond our control, and other risks and uncertainties identified

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements BIO-RAD LABORATORIES, INC. Condensed Consolidated Balance Sheets (In millions, except share data) September 30, 2025 December 31, 2024 ASSETS: (Unaudited) Current assets: Cash and cash equivalents $ 395.8 $ 488.1 Short-term investments 1,022.8 1,176.4 Accounts receivable, less allowance for credit losses of $ 6.2 and $ 9.2 as of September 30, 2025 and December 31, 2024, respectively 464.7 452.5 Inventory 783.2 760.0 Prepaid expenses 152.0 122.6 Other current assets 23.5 30.7 Total current assets 2,842.0 3,030.3 Property, plant and equipment, net 540.2 528.1 Operating lease right-of-use assets 180.3 160.5 Goodwill, net 578.7 410.5 Purchased intangibles, net 388.4 293.6 Other investments 5,057.8 4,839.2 Other assets 109.0 101.9 Total assets $ 9,696.4 $ 9,364.1 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 BIO-RAD LABORATORIES, INC. Condensed Consolidated Balance Sheets (continued) (In millions, except share data) September 30, 2025 December 31, 2024 LIABILITIES AND STOCKHOLDERS' EQUITY: (Unaudited) Current liabilities: Accounts payable $ 128.8 $ 122.3 Accrued payroll and employee benefits 182.8 124.2 Current maturities of long-term debt and notes payable 1.3 1.2 Income and other taxes payable 44.8 31.2 Current operating lease liabilities 36.8 41.7 Other current liabilities 127.8 147.2 Total current liabilities 522.3 467.8 Long-term debt, net of current maturities 1,201.4 1,200.4 Deferred income taxes 872.6 818.0 Operating lease liabilities 155.8 131.4 Other long-term liabilities 207.5 177.2 Total liabilities 2,959.6 2,794.8 Stockholders' equity: Preferred stock, $ 0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none — — Class A common stock, $ 0.0001 par value; 80,000,000 shares authorized; shares issued 25,195,734 and 25,191,463 as of September 30, 2025 and December 31, 2024, respectively; shares outstandi

View Full Filing

View this 10-Q filing on SEC EDGAR